Treatments composed of mixture of cytokines, growth factors and other active components

Aposcience AG is at the forefront of regenerative medicine, focusing on the therapeutic potential of secretomes derived from white blood cells, specifically peripheral blood mononuclear cells (PBMCs). This innovative approach aims to restore the functionality of tissues affected by various diseases rather than merely repairing them. The company is developing treatments for conditions such as impaired wound healing, including diabetic ulcers and deep skin burns, as well as internal diseases linked to ischemia-induced inflammation, such as myocardial infarction, stroke, and spinal cord injuries.

The company’s clinical pipeline includes two primary products: APO-1 (APOSEC™), an injectable formulation designed to enhance cardiac function in chronic myocardial ischemia, and APO-2 (APOSEC™), a topical formulation aimed at treating diabetic foot ulcers and other chronic wounds. Aposcience is actively conducting clinical studies to evaluate the safety and efficacy of these products, with the Marsyas I and Marsyas II studies focusing on wound healing and diabetic foot ulcers, respectively. These studies are crucial for translating promising preclinical data into effective clinical applications, addressing significant unmet medical needs in regenerative therapies.

United States

Aposcience AG aspires to improve the health of patients in need of regenerative medicine by commercially exploiting the therapeutic potential of secretomes derived from white blood cells (PBMCs) isolated from peripheral blood. PBMCs are currently a waste product of all blood transfusion units.

Aposcience

Company Details